Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor

Xilio Therapeutics, Inc.

Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.
Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.
Broker non-votes of 3,812,216 recorded on each director election.
Annual meeting held June 8, 2023; all proposals passed with strong support.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Xilio Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Xilio Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

1. The Company’s stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.

View on SEC.gov

545 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-011031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.